1. Do we need a new strategy to treat metastatic breast cancer?

   • Joseph R. Bertino
   • Owen A. O’Connor

   Invited Commentary Pages: 85 - 87

2. Web alert

   • Bassem M. Said

   News Pages: 88 - 89

3. Literature alert

   Abstract Pages: 90 - 93

4. Integration of chemotherapy into the definitive management of squamous cell head and neck cancer

   • David J. Adelstein

   Clinical Trials Review Pages: 97 - 98

5. Conservation laryngeal surgery

   • Steven C. Marks

   OriginalPaper Pages: 99 - 104

6. Concurrent chemoradiotherapy in head and neck cancer

   • Susan G. Urba

   OriginalPaper Pages: 105 - 109

7. Altered fractionation in the treatment of head and neck cancer

   • Kenneth S. Hu
   • Louis B. Harrison

   OriginalPaper Pages: 110 - 123

8. Quality-of-life issues in head and neck cancer

   • Ehab Hanna
   • Allen C. Sherman

   OriginalPaper Pages: 124 - 128

9. Clinical implications of biomarkers in head and neck cancer

   • Wayne M. Koch

   OriginalPaper Pages: 129 - 137

10. Local delivery for gene therapy

    • Gary L. Clayman
    • Lyndah Dreiling

    OriginalPaper Pages: 138 - 143

11. Immunotherapy for colorectal cancer

    • Richard L. Schilsky

    Clinical Trials Review Pages: 147 - 148

12. Combined modality therapy for esophageal cancer

    • Ziv Gamliel
    • Mark J. Krasna

    OriginalPaper Pages: 149 - 154

13. The role of irinotecan in colorectal cancer

    • Leonard B. Saltz

    OriginalPaper Pages: 155 - 160

14. Novel chemotherapy agents for colorectal cancer: Oral fluoropyrimidines, oxaliplatin, and raltitrexed

    • Melanie E. Royce
    • Paulo M. Hoff
    • Richard Padzur

    OriginalPaper Pages: 161 - 167

15. The role of carcinoembryonic antigen monitoring in management of colorectal cancer

    • Mary F. Mulcahy
    • Al B. Benson III

    OriginalPaper Pages: 168 - 172

16. Cyclooxygenase-2 as a target for prevention of colorectal cancer

    • Monica M. Bertagnolli

    OriginalPaper Pages: 173 - 178